{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:02:13Z","timestamp":1790078533962,"version":"4.0.1"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been the backbone of graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation for more than four decades. Yet, the pharmacological framework governing their therapeutic drug monitoring has been significantly imported from solid organ transplantation. This critical narrative review argues that this extrapolation is scientifically unsound. The unique biological environment of allogeneic hematopoietic cell transplantation characterized by toxic conditioning regimens, profound hematologic changes, systemic inflammation, and an unparalleled drug interaction landscape creates pharmacokinetic and pharmacodynamic conditions for which solid organ transplant-derived targets are inadequate. We critically appraise the quality of evidence underpinning current therapeutic drug monitoring practices, examine the historical divide between cyclosporine and tacrolimus use, and propose a research agenda directed at developing hematopoietic transplant-specific precision immunosuppression strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1940626","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:10:07Z","timestamp":1790075407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Calcineurin inhibitor monitoring in allogeneic hematopoietic cell transplantation: time to move beyond solid organ transplant paradigms"],"prefix":"10.3389","volume":"17","author":[{"given":"Pedro Henrique","family":"Prata","sequence":"first","affiliation":[{"name":"Department of Clinical Hematology and Cell Therapy, Centre Hospitalier Universitaire (CHU) de Limoges","place":["Limoges, France"]},{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges","place":["Limoges, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Labriffe","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges","place":["Limoges, France"]},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges","place":["Limoges, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges","place":["Limoges, France"]},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges","place":["Limoges, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges","place":["Limoges, France"]},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges","place":["Limoges, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges","place":["Limoges, France"]},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges","place":["Limoges, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197006000-00006","article-title":"A compendium of reported human bone marrow transplants","volume":"9","author":"Bortin","year":"1970","journal-title":"Transplantation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v19.2.217.217","article-title":"Marrow transplants in lethally irradiated dogs given methotrexate","volume":"19","author":"Thomas","year":"1962","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v65.6.1325.bloodjournal6561325","article-title":"Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia","volume":"65","author":"Deeg","year":"1985","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-Haploidentical bone marrow transplantation for hematologic Malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin A: a new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors","volume":"2","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90124-h","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/357695a0","article-title":"Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation","volume":"357","author":"Clipstone","year":"1992","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/365352a0","article-title":"The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun","volume":"365","author":"Jain","year":"1993","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/352803a0","article-title":"Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A","volume":"352","author":"Flanagan","year":"1991","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/341758a0","article-title":"A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase","volume":"341","author":"Harding","year":"1989","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.6238408","article-title":"Cyclophilin: a specific cytosolic binding protein for cyclosporin A","volume":"226","author":"Handschumacher","year":"1984","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410273311702","article-title":"A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","year":"1994","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00007890-199902270-00001","article-title":"Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation","volume":"67","author":"Bornh\u00e4user","year":"1999","journal-title":"Transplantation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30220-0","article-title":"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological Malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.clml.2021.05.003","article-title":"Addition of anti-thymocyte globulin in allogeneic stem cell transplantation with peripheral stem cells from matched unrelated donors improves graft-versus-host disease and relapse free survival","volume":"21","author":"Ali","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.04.010","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040613","article-title":"Effect of early post-transplantation tacrolimus concentration on the risk of acute graft-versus-host disease in allogenic stem cell transplantation","volume":"13","author":"Sharma","year":"2021","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.02.002","article-title":"Clinical effects of tacrolimus blood concentrations early after allogeneic hematopoietic stem cell transplantation","volume":"26","author":"Kubo","year":"2024","journal-title":"Cytotherapy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00014","article-title":"Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation","volume":"6","author":"Ramadan","year":"2015","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443110-00004","article-title":"Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients","volume":"43","author":"Kuypers","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/BF01046702","article-title":"Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing","volume":"34","author":"Lindholm","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00846-1","article-title":"Clinical pharmacokinetics and impact of hematocrit on monitoring and dosing of tacrolimus early after heart and lung transplantation","volume":"59","author":"Sikma","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological Malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1057-2","article-title":"Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation","volume":"95","author":"Mori","year":"2012","journal-title":"Int J Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.12.014","article-title":"Drug interaction between letermovir and tacrolimus in allogeneic hematopoietic stem cell transplant recipients: a retrospective study","volume":"27","author":"Matsuo","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2165\/11317240-000000000-00000","article-title":"Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients","volume":"48","author":"Benkali","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.1999.v5.pm10371361","article-title":"Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation","volume":"5","author":"Przepiorka","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease \u2014 biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.iac.2009.10.001","article-title":"Pathogenesis and management of graft-versus-host disease","volume":"30","author":"Choi","year":"2010","journal-title":"Immunol Allergy Clinics North America"},{"key":"B45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbmt.2018.08.018","article-title":"Comparative analysis of calcineurin inhibitor\u2013based methotrexate and mycophenolate mofetil\u2013containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation","volume":"25","author":"Chhabra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif Organs"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1675635","article-title":"Tacrolimus in adult hematopoietic stem cell transplantation","volume":"15","author":"Gao","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2015.0047","article-title":"Tacrolimus-induced diabetic ketoacidosis after allogeneic bone marrow transplant","volume":"15","author":"Solmaz","year":"2017","journal-title":"Exp Clin Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703790","article-title":"Cyclosporine therapeutic monitoring in allogeneic stem cell transplantation: comparison of different target blood cyclosporine levels","volume":"31","author":"Sohn","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B50","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12394","article-title":"Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients","volume":"78","author":"Woillard","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1517083","article-title":"Tacrolimus exposure during the three-month period following allogeneic stem cell transplantation predicts overall survival","volume":"16","author":"Zavrelova","year":"2025","journal-title":"Front Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13089","article-title":"Exposure-response relationships of immunosuppressive drugs in transplantation","volume":"31","author":"van Gelder","year":"2018","journal-title":"Transplant Int"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.02.009","article-title":"Pharmacokinetics of tacrolimus in allogeneic stem cell transplantation: a population pharmacokinetics study","volume":"22","author":"Sheridan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00007890-199907150-00011","article-title":"Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation","volume":"68","author":"Mahalati","year":"1999","journal-title":"Transplantation"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16098","article-title":"Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve-based monitoring","volume":"91","author":"van Gelder","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119877","article-title":"A novel approach to therapeutic drug monitoring of ciclosporin in pediatric renal transplant recipients using volumetric absorptive microsampling (VAMS) - Teaching old dog new tricks","volume":"562","author":"Kocur","year":"2024","journal-title":"Clin Chim Acta"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/17576180.2025.2477976","article-title":"Microsampling techniques and patient-centric therapeutic drug monitoring of immunosuppressants","volume":"17","author":"Kocur","year":"2025","journal-title":"Bioanalysis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2019-1260","article-title":"Volumetric absorptive microsampling and dried blood spot microsampling vs. conventional venous sampling for tacrolimus trough concentration monitoring","volume":"58","author":"Veenhof","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15433","article-title":"Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients","volume":"88","author":"Zwart","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/14622416.2025.2541404","article-title":"Pharmacogenetics of graft-versus-host disease: a path to personalized medicine","volume":"26","author":"\u0141acina","year":"2025","journal-title":"Pharmacogenomics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1334440","article-title":"CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Seligson","year":"2024","journal-title":"Front Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70413","article-title":"The impact of CYP3A4, CYP3A5, and ABCB1 polymorphisms on cyclosporine concentration in leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"39","author":"Salehi","year":"2025","journal-title":"Clin Transplant"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2013.78","article-title":"Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation","volume":"3","author":"Moes","year":"2014","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f9ac01","article-title":"Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients","volume":"18","author":"Fukudo","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2017-0127","article-title":"Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients","volume":"18","author":"Sun","year":"2017","journal-title":"Pharmacogenomics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1940626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:10:08Z","timestamp":1790075408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1940626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2026.1940626"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1940626","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1940626"}}